JP2003521437A5 - - Google Patents

Download PDF

Info

Publication number
JP2003521437A5
JP2003521437A5 JP2000516658A JP2000516658A JP2003521437A5 JP 2003521437 A5 JP2003521437 A5 JP 2003521437A5 JP 2000516658 A JP2000516658 A JP 2000516658A JP 2000516658 A JP2000516658 A JP 2000516658A JP 2003521437 A5 JP2003521437 A5 JP 2003521437A5
Authority
JP
Japan
Prior art keywords
inhibitor
renin
pharmaceutical composition
composition according
angiotensin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000516658A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003521437A (ja
JP5187991B2 (ja
Filing date
Publication date
Priority claimed from GBGB9722026.3A external-priority patent/GB9722026D0/en
Priority claimed from GBGB9810855.8A external-priority patent/GB9810855D0/en
Application filed filed Critical
Priority claimed from PCT/GB1998/003122 external-priority patent/WO1999020260A2/en
Publication of JP2003521437A publication Critical patent/JP2003521437A/ja
Publication of JP2003521437A5 publication Critical patent/JP2003521437A5/ja
Application granted granted Critical
Publication of JP5187991B2 publication Critical patent/JP5187991B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000516658A 1997-10-17 1998-10-19 レニン−アンジオテンシン系の阻害剤の使用 Expired - Fee Related JP5187991B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9722026.3 1997-10-17
GBGB9722026.3A GB9722026D0 (en) 1997-10-17 1997-10-17 Use of compounds
GBGB9810855.8A GB9810855D0 (en) 1998-05-20 1998-05-20 Use of compounds
GB9810855.8 1998-05-20
PCT/GB1998/003122 WO1999020260A2 (en) 1997-10-17 1998-10-19 The use of inhibitors of the renin-angiotensin system for the treatment of hypoxia or impaired metabolic function

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009166483A Division JP2009242426A (ja) 1997-10-17 2009-07-15 レニン−アンジオテンシン系の阻害剤の使用

Publications (3)

Publication Number Publication Date
JP2003521437A JP2003521437A (ja) 2003-07-15
JP2003521437A5 true JP2003521437A5 (cg-RX-API-DMAC7.html) 2006-01-05
JP5187991B2 JP5187991B2 (ja) 2013-04-24

Family

ID=26312447

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000516658A Expired - Fee Related JP5187991B2 (ja) 1997-10-17 1998-10-19 レニン−アンジオテンシン系の阻害剤の使用
JP2009166483A Pending JP2009242426A (ja) 1997-10-17 2009-07-15 レニン−アンジオテンシン系の阻害剤の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009166483A Pending JP2009242426A (ja) 1997-10-17 2009-07-15 レニン−アンジオテンシン系の阻害剤の使用

Country Status (19)

Country Link
US (7) US7071183B2 (cg-RX-API-DMAC7.html)
EP (4) EP1023067B2 (cg-RX-API-DMAC7.html)
JP (2) JP5187991B2 (cg-RX-API-DMAC7.html)
KR (3) KR100572080B1 (cg-RX-API-DMAC7.html)
CN (1) CN1123342C (cg-RX-API-DMAC7.html)
AP (1) AP1300A (cg-RX-API-DMAC7.html)
AT (2) ATE294579T1 (cg-RX-API-DMAC7.html)
AU (1) AU742506B2 (cg-RX-API-DMAC7.html)
CA (2) CA2677910C (cg-RX-API-DMAC7.html)
CY (1) CY1106813T1 (cg-RX-API-DMAC7.html)
DE (2) DE69830069T3 (cg-RX-API-DMAC7.html)
DK (2) DK1498124T3 (cg-RX-API-DMAC7.html)
ES (2) ES2238770T5 (cg-RX-API-DMAC7.html)
HU (2) HU0900792D0 (cg-RX-API-DMAC7.html)
NO (1) NO326231B1 (cg-RX-API-DMAC7.html)
PL (2) PL197164B1 (cg-RX-API-DMAC7.html)
PT (2) PT1498124E (cg-RX-API-DMAC7.html)
UY (2) UY25971A1 (cg-RX-API-DMAC7.html)
WO (1) WO1999020260A2 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101011390A (zh) 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
DK1216038T3 (da) 1999-08-30 2005-12-27 Sanofi Aventis Deutschland Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser
EA005310B1 (ru) * 2000-04-10 2004-12-30 Юити Исида Гипотензивные средства
WO2002099098A1 (en) * 2001-04-04 2002-12-12 American Diagnostica, Inc Method of preparation of stabilized thrombin-activatable fibrinolysis inhibitor (tafi) and methods of use thereof
GB0119460D0 (en) * 2001-08-09 2001-10-03 Ark Therapeutics Ltd The use of inhibitors of the renin-angiotensin system
BR0214383A (pt) * 2001-11-23 2004-11-03 Solvay Pharm Gmbh Tratamento de hipertonia durante a fase aguda do ataque de apoplexia
EP1382334A1 (en) * 2002-07-11 2004-01-21 Université de Picardie Jules Verne Use of angiotensin II AT1-receptor blockers (ARB), alone or combined with thiazide or angiotensin II for the treatment of stroke
ES2344641T3 (es) 2002-08-29 2010-09-02 American Diagnostica, Inc. Ensayo de diagnostico para determinar inhibidor de fibrinolisis activable por trombina (tafi).
EP1600166A4 (en) * 2003-01-17 2008-02-27 Takeda Pharmaceutical SKELETAL MUSCLE PROTECTIVE AGENT
WO2005084648A1 (en) * 2004-02-27 2005-09-15 Ranbaxy Laboratories Limited Pharmaceutical compositions comprising candesartan cilexetil
WO2005118166A2 (en) 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
WO2006009325A1 (ja) * 2004-07-23 2006-01-26 Ono Pharmaceutical Co., Ltd. メタロプロテアーゼ阻害剤
CA2646131C (en) * 2005-03-21 2018-09-04 Vicus Therapeutics Spe 1, Llc Compositions and methods for ameliorating cachexia
AR068814A1 (es) * 2007-08-29 2009-12-09 Orion Corp Composicion farmaceutica que comprende levosimendan y un inhibidor de la enzima conversina de la angiotensina (ace), y uso
CN101951921A (zh) * 2007-09-17 2011-01-19 比奥尼里斯有限责任公司 用于治疗恶病质的方法和手段
RU2393857C2 (ru) * 2008-05-12 2010-07-10 Государственное образовательное учреждение высшего профессионального образования Читинская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию Лекарственное средство, оказывающее противосудорожное и антигипоксическое действие
US10517839B2 (en) * 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
WO2012135597A2 (en) 2011-03-30 2012-10-04 The Johns Hopkins University Novel, protective, anti-inflammatory receptor and its use in preservation of mitochondrial function, wound healing and repair
KR20130074808A (ko) * 2011-12-16 2013-07-05 한올바이오파마주식회사 스타틴계 지질저하제에 의한 근육계 부작용의 치료 또는 예방을 위한 로사르탄을 포함하는 약제학적 조성물
EP2832357A1 (en) 2013-07-29 2015-02-04 Charité - Universitätsmedizin Berlin Selective AT2 receptor agonists for use in treatment of cachexia
US20160334389A1 (en) * 2014-01-14 2016-11-17 Won Cheol Choi Method for screening cancer prevention agent or anticancer agent using morphological characteristics of luterial
JP2016183174A (ja) * 2016-05-12 2016-10-20 ディフュージョン・ファーマシューティカルズ・エルエルシー 双極性トランスカロテノイド塩及びそれらの使用
CA3103599A1 (en) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for treatment of hypertension with an angiotensin ii receptor blocker pharmaceutical composition
DE202023100085U1 (de) 2023-01-09 2023-02-03 Sundararajan Gothandam Eine doppelte Blockade des Renin-Angiotensin-Systems zur Verringerung der frühen Veränderungen der diabetischen Retinopathie und Nephropathie

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2655989B1 (fr) * 1989-12-20 1992-02-28 Adir Nouveaux derives d'amino-acides substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5049553A (en) * 1990-01-04 1991-09-17 E. R. Squibb & Sons, Inc. Method for preventing or treating symptoms resulting from closed head injuries employing an ace inhibitor
GB2241890A (en) 1990-03-12 1991-09-18 Squibb & Sons Inc Preventing onset of or treating protein catabolism using an ace inhibitor
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
CA2048699A1 (en) * 1990-09-04 1992-03-05 Abraham Sudilovsky Method for preventing or treating cerebro-vascular disease employing ceronapril
CA2052014A1 (en) 1990-10-19 1992-04-20 Henry Y. Pan Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor
TW197945B (cg-RX-API-DMAC7.html) * 1990-11-27 1993-01-11 Hoechst Ag
FI905896A7 (fi) * 1990-11-29 1992-05-30 Valmet Paper Machinery Inc Formningsgapsarrangemang i en dubbelviraformare av en pappersmaskin.
GB9027199D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
SI9210098B (sl) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5614519A (en) * 1991-02-06 1997-03-25 Karl Thomae Gmbh (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists
GB9108811D0 (en) * 1991-04-24 1991-06-12 Erba Carlo Spa N-imidazolyl derivatives of substituted indole
AU3968193A (en) 1992-03-26 1993-10-21 Gensia, Inc. In vivo peptide therapy
US5972990A (en) * 1992-04-10 1999-10-26 Brigham And Women's Hospital, Inc. Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
US5374643A (en) * 1992-09-11 1994-12-20 E. R. Squibb & Sons, Inc. Aryl urea (thiourea) and cyanoguanidine derivatives
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5824696A (en) * 1993-09-01 1998-10-20 Smithkline Beecham Corporation Medicaments
US5464854A (en) * 1993-11-11 1995-11-07 Depadova; Anathony S. Method of modifying ovarian hormone-regulated AT1 receptor activity as treatment of incapacitating symptom(s) of P.M.S.
CA2140722A1 (en) * 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline thromboxane synthase inhibitors
US5550118A (en) * 1994-01-31 1996-08-27 Eli Lilly And Company Polyhydronorharman synthase inhibitors
US5468757A (en) * 1994-01-31 1995-11-21 Eli Lilly And Company 6-azaindole thromboxane synthase inhibitors
DE4410997A1 (de) * 1994-03-30 1995-10-26 Isis Pharma Gmbh Pharmazeutische Zubereitungen und Arzneistoffe zur Prävention und Behandlung endothelialer Dysfunktionen
DE4420102A1 (de) 1994-06-09 1995-12-14 Asta Medica Ag Arzneimittelkombinationen aus alpha-Liponsäure und herz-kreislaufaktiven Substanzen
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5559135A (en) * 1994-09-14 1996-09-24 Merck & Co., Inc. Endothelin antagonists bearing pyridyl amides
US5538991A (en) * 1994-09-14 1996-07-23 Merck & Co., Inc. Endothelin antagonists bearing 5-membered heterocyclic amides
US5645839A (en) * 1995-06-07 1997-07-08 Trustees Of Boston University Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
TW356468B (en) * 1995-09-15 1999-04-21 Astra Pharma Prod Benzothiazolone compounds useful as beta2-adrenoreceptor and dopamine DA2 receptor agonists process for preparing same and pharmaceutical compositions containing same
JPH11513395A (ja) * 1995-10-06 1999-11-16 ノバルティス・アクチエンゲゼルシャフト 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのat1−レセプターアンタゴニスト
CA2238975A1 (en) * 1995-12-12 1997-06-19 Merck & Co., Inc. New use for losartan
US6258032B1 (en) * 1997-01-29 2001-07-10 William M. Hammesfahr Method of diagnosis and treatment and related compositions and apparatus
US6420412B2 (en) * 1996-03-29 2002-07-16 Smithkline Beecham Corporation Eprosartan dihydate and a process for its production and formulation
DE19614533A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung
DE19614542A1 (de) * 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
US20040122096A1 (en) * 1996-06-03 2004-06-24 Hoechst Aktiengesellschaft Use of inhibitors of the cellular Na+/H+ exchanger (NHE) for preparing a medicament for normalizing serum lipids
DE19636046A1 (de) * 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
CN1230178A (zh) 1996-09-10 1999-09-29 麦地诺克斯公司 含聚二硫代氨基甲酸酯的大分子和其用于治疗和诊断应用的用途
US6008221A (en) 1996-11-06 1999-12-28 Bristol-Myers Squibb Company Method for treating Alzheimer's disease with folic acid
US6448248B1 (en) * 1996-12-18 2002-09-10 Abbott Laboratories Heterocyclic carboxylic acid derivatives, the production and use thereof as endothelin receptor antagonists
EP0855392A3 (de) * 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US6197505B1 (en) * 1997-04-04 2001-03-06 Pyrosequencing Ab Methods for assessing cardiovascular status and compositions for use thereof
US5916910A (en) 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
DK1216038T3 (da) * 1999-08-30 2005-12-27 Sanofi Aventis Deutschland Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser

Similar Documents

Publication Publication Date Title
CA2306216A1 (en) The use of inhibitors of the renin-angiotensin system for the treatment of cachexia and wasting
Stanton Therapeutic potential of renin inhibitors in the management of cardiovascular disorders
RU2002129558A (ru) КОМБИНАЦИЯ ПО МЕНЬШЕЙ МЕРЕ ДВУХ СОЕДИНЕНИЙ, ВЫБРАННЫХ ИЗ ГРУПП АНТАГОНИСТОВ АТ,-РЕЦЕПТОРА ИЛИ ИНГИБИТОРОВ АСЕ(АНГИОТЕНЗИНПРЕВРАЩАЮЩИЙ ФЕРМЕНТ) ИЛИ ИНГИБИТОРОВ HMG-COA-РЕДУКТАЗЫ (β-ГИДРОКСИ-β-МЕТИЛГЛУТАРИЛ-КОФЕРМЕНТ-А-РЕДУКТАЗА)
Stanton Potential of renin inhibition in cardiovascular disease
JP2003527325A5 (cg-RX-API-DMAC7.html)
PE20020229A1 (es) COMBINACION DE UN ANTAGONISTA DEL RECEPTOR AT1; UN INHBIDOR DE HMG-CoA REDUCTASA Y UN INHIBIDOR DE ACE
RU2006147220A (ru) Композиции, включающие в себя небиволол
FI4076652T3 (fi) Farmaseuttisesti hyväksyttävä atrasentanin suola käytettäväksi iga-nefropatiaan hoitomenetelmässä
RU2002107985A (ru) Применение ингибиторов ренин-ангиотензиновой системы для профилактики сердечно-сосудистых явлений
JP2004513920A5 (cg-RX-API-DMAC7.html)
NZ701609A (en) Liquid formulation comprising propylene glycol and an inodilator
WO2001015674A3 (en) Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
JP2018507244A5 (cg-RX-API-DMAC7.html)
RU2014110401A (ru) Ингибиторы внешнего медуллярного калиевого канала почек
JP2003508426A5 (cg-RX-API-DMAC7.html)
WO2006086456A3 (en) Combination of organic compounds
RU2017104111A (ru) Ингибиторы внешнего медуллярного калиевого канала
RU2015110979A (ru) Комбинации ингибиторов sglt 2 и антигипертензивных лекарственных средств
Mollace et al. Modulation of RAAS-natriuretic peptides in the treatment of HF: old guys and newcomers
RU2017104110A (ru) Ингибиторы внешнего медуллярного калиевого канала почек
WO2007056324A3 (en) Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent
Fournier et al. Is the angiotensin II type 2 receptor cerebroprotective?
JP2001501908A (ja) 消化不良症候の治療のためのace阻害剤の新規な医療への使用
CA2304712C (en) Endothelin antagonist and a renin-angiotensin system inhibitor as a combined preparation
RU2001122113A (ru) Применение антагонистов рецептора ангиотензина II для лечения острого инфаркта миокарда